Royal Bank of Canada Analysts Give Charles River Laboratories Intl. (CRL) a $147.00 Price Target

Share on StockTwits

Royal Bank of Canada set a $147.00 price target on Charles River Laboratories Intl. (NYSE:CRL) in a research report report published on Wednesday, MarketBeat reports. The firm currently has a buy rating on the medical research company’s stock.

Several other analysts also recently commented on the company. Robert W. Baird raised their target price on Charles River Laboratories Intl. from $133.00 to $141.00 and gave the company an outperform rating in a research note on Monday, September 17th. Credit Suisse Group reduced their target price on Charles River Laboratories Intl. from $129.00 to $121.00 and set a neutral rating for the company in a research note on Tuesday, August 21st. Raymond James upgraded Charles River Laboratories Intl. from a market perform rating to an outperform rating and set a $140.00 target price for the company in a research note on Thursday, August 23rd. ValuEngine downgraded Charles River Laboratories Intl. from a buy rating to a hold rating in a research note on Tuesday, August 28th. Finally, Argus raised their target price on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the company a buy rating in a research note on Monday, August 27th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $130.56.

Shares of CRL traded up $0.35 during trading hours on Wednesday, hitting $136.45. The stock had a trading volume of 592,301 shares, compared to its average volume of 384,159. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. The company has a market cap of $6.54 billion, a PE ratio of 25.89, a P/E/G ratio of 1.71 and a beta of 0.74. Charles River Laboratories Intl. has a 1-year low of $96.70 and a 1-year high of $138.89.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.15. The company had revenue of $585.30 million during the quarter, compared to the consensus estimate of $567.58 million. Charles River Laboratories Intl. had a return on equity of 25.81% and a net margin of 6.39%. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period last year, the business posted $1.30 EPS. Analysts expect that Charles River Laboratories Intl. will post 5.93 EPS for the current fiscal year.

In other Charles River Laboratories Intl. news, Director Deborah Turner Kochevar sold 4,066 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $123.66, for a total transaction of $502,801.56. Following the transaction, the director now owns 10,190 shares of the company’s stock, valued at approximately $1,260,095.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $120.05, for a total transaction of $149,942.45. Following the transaction, the insider now directly owns 13,690 shares in the company, valued at approximately $1,643,484.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,671 shares of company stock worth $3,829,160. 2.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund lifted its position in shares of Charles River Laboratories Intl. by 2.6% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 18,893 shares of the medical research company’s stock worth $2,542,000 after buying an additional 484 shares in the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Charles River Laboratories Intl. by 1.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 30,113 shares of the medical research company’s stock worth $3,380,000 after buying an additional 515 shares in the last quarter. Investment House LLC lifted its position in shares of Charles River Laboratories Intl. by 0.7% during the 3rd quarter. Investment House LLC now owns 94,470 shares of the medical research company’s stock worth $12,710,000 after buying an additional 615 shares in the last quarter. Putnam Investments LLC lifted its position in shares of Charles River Laboratories Intl. by 1.0% during the 2nd quarter. Putnam Investments LLC now owns 70,913 shares of the medical research company’s stock worth $7,961,000 after buying an additional 680 shares in the last quarter. Finally, Sawgrass Asset Management LLC raised its holdings in shares of Charles River Laboratories Intl. by 33.0% in the 2nd quarter. Sawgrass Asset Management LLC now owns 2,900 shares of the medical research company’s stock worth $326,000 after purchasing an additional 720 shares during the period. 96.93% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Stock Symbol

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rent-A-Center  Upgraded to Buy by BidaskClub
Rent-A-Center Upgraded to Buy by BidaskClub
Grand Canyon Education  Downgraded by BidaskClub to Buy
Grand Canyon Education Downgraded by BidaskClub to Buy
TFS Financial  Upgraded at ValuEngine
TFS Financial Upgraded at ValuEngine
Cheesecake Factory  Upgraded at BidaskClub
Cheesecake Factory Upgraded at BidaskClub
Uniti Group  Cut to Sell at Zacks Investment Research
Uniti Group Cut to Sell at Zacks Investment Research
Royal Bank of Scotland Group  Lowered to Strong Sell at ValuEngine
Royal Bank of Scotland Group Lowered to Strong Sell at ValuEngine


Leave a Reply

© 2006-2018 Ticker Report